drug nintedanib was previously used to treat cancer and has been shown to slow the progress of idiopathic pulmonary fibrosis .
the drug is now likely to be licensed worldwide within the next year , and avail-able to patients in the near future .
the condition affects mainly men and former smokers , causes inflammation and scarring of the lung tissue .